Gusan S, Anand-Srivastava MB. cAMP attenuates the enhanced expression of G i proteins and hyperproliferation of vascular smooth muscle cells from SHR: role of ROS and ROS-mediated signaling. Am J Physiol Cell Physiol 304: C1198 -C1209, 2013. First published April 10, 2013; doi:10.1152/ajpcell.00269.2012.-We previously showed that angiotensin II (ANG II)-induced overexpression of inhibitory G proteins (G i) was attenuated by dibutyryl-cAMP (db-cAMP) in A10 vascular smooth muscle cells (VSMC). Since enhanced levels of endogenous ANG II contributed to the overexpression of G i protein and hyperproliferation of VSMC from spontaneously hypertensive rats (SHR), the present study was therefore undertaken to examine if cAMP could also attenuate the overexpression of G i proteins and hyperproliferation of VSMC from SHR and to explore the underlying molecular mechanisms responsible for this response. The enhanced expression of G i␣ proteins in VSMC from SHR and N -nitro-Larginine methyl ester hypertensive rats was decreased by db-cAMP. In addition, enhanced inhibition of adenylyl cyclase by inhibitory hormones and forskolin-stimulated adenylyl cyclase activity by low concentration of GTP␥S in VSMC from SHR was also restored to Wistar-Kyoto (WKY) levels by db-cAMP. Furthermore, db-cAMP also attenuated the hyperproliferation and the increased production of superoxide anion, NAD(P)H oxidase activity, overexpression of Nox1/Nox2/Nox4 and p47 phox proteins, increased phosphorylation of PDGF-receptor (R), EGF-R, c-Src, and ERK1/2 to control levels. In addition, the protein kinase A (PKA) inhibitor reversed the effects of db-cAMP on the expression of Nox4 and Gi␣ proteins and hyperproliferation of VSMC from SHR to WKY levels, while stimulation of the exchange protein directly activated by cAMP did not have any effect on these parameters. These results suggest that cAMP via PKA pathway attenuates the overexpression of Gi proteins and hyperproliferation of VSMC from SHR through the inhibition of ROS and ROS-mediated transactivation of EGF-R/PDGF-R and MAPK signaling pathways.
3=-5=-CYCLIC ADENOSINE MONOPHOSPHATE (cAMP), a second messenger produced by the adenylyl cyclase signal transduction system, plays an important role in the regulation of a variety of physiological functions including cardiac contractility, vascular smooth muscle tone, cell proliferation, and protein synthesis (8, 10, 14, 26) . The adenylyl cyclase activity and the levels of cAMP are regulated by two guanine nucleotide regulatory proteins (G proteins), stimulatory (G s ) and inhibitory (G i ), that mediate the stimulatory and inhibitory responses of the hormones, respectively, to adenylyl cyclase (48) and increase or decrease the levels of cAMP. G proteins are heterotrimers composed of ␣-, ␤-, and ␥-subunits. The ␣-subunit is responsible for binding and hydrolyzing GTP and confers specificity in receptor and effector interaction. Four different isoforms of G s ␣ proteins resulting from the differential splicing of a single gene (18, 52) and three distinct forms of G i ␣ proteins (G i ␣-1, G i ␣-2, and G i ␣-3) encoded by three distinct genes have been identified (33) . All three forms of G i ␣ (G i ␣-1 to G i ␣-3) are implicated in adenylyl cyclase inhibition (33) and in the activation of atrial K ϩ channel (62) . Alterations in the levels of G i protein and associated decreased adenylyl cyclase signaling have been linked to impaired cellular functions leading to various pathological states, including hypertension, hypertrophy, and cardiac failure (4, 26, 34, 57) . Several abnormalities in G i protein expression, adenylyl cyclase activity, and cAMP levels have been reported in cardiovascular tissues from genetic models [spontaneously hypertensive rats (SHR)] and different models of experimentally induced hypertensive rats (2, 4, 5, 7, 15, 57 ). An increased expression of G i protein and G i protein mRNA resulting in decreased levels of cAMP has been reported in hearts and aortas from SHR and in hearts from deoxycorticosterone acetate (DOCA)-salt hypertensive rats and N -nitro-L-arginine methyl ester (L-NAME) hypertensive rats (4, 5, 24, 57) . The increased expression of G i ␣ proteins was shown to occur before the onset of hypertension in SHR and in DOCA-salt hypertensive rats, suggesting that the enhanced levels of G i ␣ proteins and associated decreased levels of cAMP may be one of the contributing factors in the pathogenesis of hypertension (44, 45) . This was further supported by our studies showing that the inactivation of G i ␣ protein by pertussis toxin in 2-wk-old SHR (prehypertensive state) that attenuated the inhibition of adenylyl cyclase and increased the levels of cAMP also resulted in the attenuation of blood pressure in SHR (38) .
The levels of G i proteins have been shown to be regulated by several modulators including vasoactive peptides, nitric oxide, cGMP, etc. (11, 12, 16, 50) . We have shown earlier that vasoactive peptides such as angiotensin II (ANG II), endothelin (ET-1), and arginine vasopressin increased (16, 17, 50) , whereas atrial natriuretic peptide (ANP), C-ANP 4 -23 , NO donors, S-nitroso-N-acetyl-penicillamine, sodium nitroprusside, and cGMP decreased, the expression of G i ␣ proteins in A10 vascular smooth muscle cells (VSMC; Refs. 3, 11, 12) . ANG II-induced enhanced expression of G i ␣ proteins was shown to be restored to control levels by dibutyryl-cAMP (db-cAMP), suggesting the implication of decreased levels of intracellular cAMP in ANG II-induced enhanced expression of G i ␣ proteins in A10 VSMC (37) . In addition, enhanced levels of G i ␣ proteins exhibited by VSMC from SHR were shown to be attributed to the enhanced oxidative stress due to the increased levels of superoxide anion (O 2 Ϫ ), NAD(P)H oxidase activity and increased expression of the NAD(P)H oxidase subunits p47 phox and Nox4 (54) . Furthermore, the enhanced levels of endogenous ANG II and ET-1 in VSMC from SHR were shown to contribute to the enhanced expression of G i ␣ proteins through oxidative stress-induced transactivation of growth factor receptors and MAPK signaling (27, 55) . The present study was therefore undertaken to investigate if db-cAMP that was reported to attenuate ANG II-induced increased expression of G i ␣ proteins in A10 VSMC (37) could also attenuate the enhanced expression of G i proteins and hyperproliferation of VSMC from SHR and to further explore the underlying signaling pathways in this response.
We provide evidence that db-cAMP attenuates the enhanced expression of G i proteins and hyperproliferation of VSMC from SHR through the inhibition of oxidative stress and c-Src and activation of growth factors receptors and MAPK signaling pathways.
MATERIALS AND METHODS
Adenosine triphosphate, dibutyryl cyclic AMP, forskolin, and isoproterenol were purchased from Sigma-Aldrich (St. Louis, MO). Creatinine kinase, myokinase (EC 2.7.4.3), guanosine 5=-[3=-thio-]triphosphate (GTP␥S), guanosine triphosphate (GTP), and adenosine deaminase (EC 3.5.4.4) were purchased from Boehringer-Mannheim (Montreal, QC, Canada). [␣-
32 P]ATP (3,000 Ci/mmol) and [methyl-3 H]thymidine (88.9 Ci/mmol) were from PerkinElmer (Boston, MA). Antibodies against G i␣-2 (L5), Gi␣-3 (C-10), p-EGF-receptor (R) (phospho-specific-tyrosine 1173 ), EGF-R (1005), p-PDGF-R (phosphospecific-tyrosine 857 ), PDGF-R (958), p-c-Src (phospho-specific-tyrosine 419 ), c-Src (N-16), p-ERK1/2 (phospho-specific-tyrosine 204 ), ERK1/2 (C-14), Nox1 (H-15), Nox2 (C-15), NOX4 (N-15), p47 phox (D-10) dynein (74 -1), KT5720 (KT), and 8-CPT-2=-O-Me-cAMP (CPT) were purchased from Santa-Cruz Biotechnologies (Santa Cruz, CA). All other chemicals used in these experiments were purchased from Sigma-Aldrich.
Animals. Hypertension in Sprague-Dawley rats was induced by the oral administration of the arginine analog L-NAME (100 mg·kg Ϫ1 ·day Ϫ1 ) in their drinking tap water for a period of 4 wk as Fig. 1 . Effect of various concentrations dibutyryl (db)-cAMP on the levels of Gi␣-2 and Gi␣-3 proteins in vascular smooth muscle cells (VSMC) from 12-wk-old spontaneously hypertensive rats (SHR) and Wistar-Kyoto (WKY) and N -nitro-L-arginine methyl ester (L-NAME) hypertensive rats and their control Sprague-Dawley rats. VSMC from SHR and WKY were incubated in the absence (control) or presence of db-cAMP (0.1, 0.3, 0.5, and 1 mM) and VSMC from L-NAME hypertensive rats (HR) and control rats were incubated in the absence (control) or presence of 0.5 mM of db-cAMP for 16 h. Cell lysates were prepared and subjected to Western blot analysis using specific antibodies against Gi␣-2 (A and C) and Gi␣-3 (B and D) as described in MATERIALS AND METHODS. Protein bands were quantified by densitometric scanning. Results are expressed as ratio of Gi protein/dynein of WKY taken as 100%. Values are means Ϯ SE of 4 separate experiments. **P Ͻ 0.01, ***P Ͻ 0.001 vs. control rats. #P Ͻ 0.05, ##P Ͻ 0.01, ###P Ͻ 0.001 vs. SHR and L-NAME HR. described previously (24) . The control rats were given plain tap water only. The arterial blood pressure (mmHg) was measured after 4 wk of treatment by the tail-cuff method without anesthesia, and the rats were killed by decapitation. The aortas were removed for the primary cell culture. All the animal procedures used in the present studies were reviewed and approved by the Comité de Déontologie de l=Expéri-mentation sur les Animaux of the University of Montreal (no. 99050). The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH Publication No. 85-23, revised 1996) .
Cell culture and incubation. VSMC from 12-wk-old SHR and Wistar-Kyoto (WKY) and L-NAME hypertensive rats and their control Sprague-Dawley rats were cultured from aortas as described previously (6) . The purity of the cells was checked by immunofluorescence technique using ␣-actin as described previously (41) . These cells were found to contain high levels of smooth muscle-specific actin. The cells were plated in 75-cm 2 flasks and incubated at 37°C in 95% air-5% CO2 humidified atmosphere in DMEM (with glucose, L-glutamine, and sodium bicarbonate) containing antibiotics and 10% heat-inactivated FBS. The cells were passaged upon reaching confluence with 0.5% trypsin containing 0.2% EDTA and utilized between passages 4 and 12. Subconfluent cells cultures were then starved by incubation for 3 h in DMEM without FBS at 37°C to reduce the interference by growth factors present in the serum. The cells were then incubated in the absence or presence of 0.5 mM or different concentrations of db-AMP (0.1, 0.3, 0.5, and 1 mM), 2 M KT, or 500 M CPT for 16 h. After incubation, the cells were washed twice with ice-cold PBS and lysed in a 200 l buffer (lysis) containing 25 mM Tris·HCl (pH 7.5), 1 mM sodium orthovanadate, 25 mM NaCl, 10 mM sodium fluoride, 10 mM sodium pyrophosphate, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, 1% Triton X-100, 0.1% sodium dodecyl sulfate, and 0.5 g/ml leupeptin on ice. The cell lysates were centrifuged at 12,000 rpm for 10 min at 4°C, and the supernatants were used for Western blot analysis.
Adenylyl cyclase activity determination. Adenylyl cyclase activity was determined by measurement of [ 32 P]cAMP formation from [␣-32 P]ATP, as described previously (31, 44) . The assay medium contained 50 mM glycylglycine (pH 7.5), 0.5 mM MgATP, [␣-32 P]ATP (1.5 ϫ 10 6 counts/min), 5 mM MgCl2 (in excess of ATP concentration), 100 mM NaCl, 0.5 mM cAMP, 1 mM IBMX, 0.1 mM EGTA, 10 M GTP␥S, and an ATP-regenerating system consisting of 2 mM cretainine phosphate, 0.1 mg/ml creatinine kinase, and 0.1 mg/ml myokinase in a final volume of 200 l. Incubations were initiated by the addition of the membrane protein (20 -40 g ) to the reaction mixture that was preincubated for 2 min at 37°C. The reactions (in triplicate) were conducted for 10 min at 37°C and were terminated by the addition of 0.6 ml of 120 mM zinc acetate containing 0.5 mM unlabeled cAMP. cAMP was purified by coprecipitation of other nucleotides with ZnCO 3 by addition of 0.5 ml of 144 mM Na2CO3 and subsequent chromatography using double-column system, as described previously (36, 44) .
Western blot analysis. Western blotting of Gi␣-2, Gi␣-3, ERK1/2, EGF-R, PDGF-R, c-Src, p47 phox , Nox1, Nox2, and Nox4 was performed as described previously (4, 5) . After SDS-PAGE, the separated proteins were electrophoretically transferred to a nitrocellulose membrane (Bio-Rad Laboratories, Mississauga, ON, Canada) with a semidry transblot apparatus (Bio-Rad Laboratories) at 15 V for 45 min (G i␣-2, Gi␣-3, ERK1/2, c-Src, p47 phox , Nox1, Nox2, and Nox4) or a liquid transfer apparatus (Bio-Rad Laboratories) at 100 V for 1 h (EGF-R and PDGF-R). After transfer, the membranes were washed twice in PBS and incubated in PBS containing 5% skim milk at room temperature for 1 h. The blots were then incubated with specific antibodies against different proteins: L5 against G i␣-2, C-10 against Gi␣-3, E-4 against p-ERK1/2, C-14 against ERK1/2, phospho-specific 
ECL Western blotting detection reagents (Amersham, ON, Canada).
Quantitative analysis of the protein was performed by densitometric scanning of the autoradiographs employing the enhanced laser densitometer LKB Ultroscan XL and quantified using the Gelscan XL evaluation software (version 2.1) from Pharmacia (Baie d'Urfé, QC, Canada).
Superoxide anion measurements.
Basal superoxide anion production in whole VSMC was measured using the lucigenin-ECL method with a low concentration (5 M) of lucigenin as described previously (61) . After treatment with db-cAMP (0.1, 0.3, 0.5, and 1 mM), the cells were washed in oxygenated Kreb-HEPES buffer, scraped, and placed in scintillation vials containing lucigenin solution, and the emitted luminescence was measured with a liquid scintillation counter (Wallac 1409; PerkinElmer Life Science, St-Laurent, QC, Canada) for 5 min. The average luminescence value was estimated, the background value was subtracted, and the result was divided by the concentration of proteins in each sample.
NAD(P)H oxidase activity determination.
After the emitted luminescence for basal superoxide anion production was measured, 0.1 mM NADPH was added in the vials and the luminescence was measured continuously for 5 min in a liquid scintillation counter (Wallac 1409; PerkinElmer Life Science). NAD(P)H oxidase activity was calculated by subtracting the basal superoxide-induced luminescence from the luminescence value induced by NADH.
Determination of cell proliferation. Cell proliferation was quantified by DNA synthesis and by directly counting the cell number. DNA synthesis was evaluated by incorporation of [ 3 H]thymidine into cells as described previously (40) . Subconfluent VSMC from SHR and WKY rats were plated in six-well plates for 24 h and were serum deprived for 24 h to induce cell quiescence. Confluent cells were then incubated with db-cAMP (0.5 mM), forskolin (100 M), KT (2 M), or CPT (500 M) for 16 h. [ 3 H]thymidine (1 Ci) was added and further incubated for 4 h before the cells were harvested. The cells were rinsed twice with ice-cold PBS and incubated with 5% trichloroacetic acid for 1 h at 4°C. After being washed twice with ice-cold water, the cells were incubated with 0.4 N sodium hydroxide solution for 30 min at room temperature, and radioactivity was determined by liquid scintillation counter. Cell viability was checked by the Trypan blue exclusion technique, which indicated that Ͼ90 -95% of cells were viable. Cell counts were determined by counting the viable cells in a hemocytometer by Trypan blue dye exclusion assay.
Statistical analysis. Data are expressed as means Ϯ SE and were analyzed using one-way ANOVA in conjunction with Newman-Keuls test. A mean difference between groups was considered statistically significant at P Ͻ 0.05.
RESULTS

db-cAMP attenuates the enhanced expression of G i proteins in VSMC from SHR.
To investigate the role of decreased level of intracellular cAMP reported in VSMC from SHR (2) in the enhanced expression of G i ␣ proteins in VSMC from SHR, we increased the levels of intracellular cAMP by db-cAMP, a permeable analog of cAMP, and examined the effect of different concentrations (0.1, 0.3, 0.5, and 1 mM) on the enhanced expression of G i ␣-2 and G i ␣-3 proteins in VSMC from SHR (Fig. 1) . G i ␣-1 is absent in VSMC (23) . As reported earlier (36) , VSMC from SHR exhibited enhanced expression of G i ␣-2 (Fig. 1A) and G i ␣-3 (Fig. 1B) proteins by ϳ60 and 40%, respectively, compared with VSMC from WKY and db-cAMP decreased the enhanced expression of G i ␣-2 and G i ␣-3 proteins in a concentration-dependent manner with maximum effect (100% decrease) at 0.5 mM. On the other hand, this treatment did not significantly affect the levels of G i ␣ proteins in VSMC from WKY rats. To further investigate if db-cAMP treatment could also restore the enhanced expression of G i ␣ proteins to control levels in other models of hypertensive rats, we used L-NAME hypertensive rats (the systolic blood pressure in L-NAME-treated rats compared with control rats was 190 Ϯ 9.2 mmHg vs. 121 Ϯ 6.3 mmHg), which were shown to exhibit enhanced expression of G i ␣ proteins (24) . As shown in Fig. 1, C and D, the enhanced expression of G i ␣-2 (75%) and G i ␣-3 (50%), respectively, in VSMC from L-NAME hypertensive rats was restored to control levels by db-cAMP (0.5 mM). However, it did not have any effect on the basal levels of G i ␣ proteins.
db-cAMP attenuates the enhanced functions of G i ␣ proteins in VSMC from SHR receptor-dependent functions. Since the enhanced expression of G i ␣-2 and G i ␣-3 proteins in VSMC from SHR is attributed to the decreased levels of intracellular cAMP, it was of interest to examine if the enhanced functions of G i proteins reported earlier in VSMC from SHR (4) were also due to the decreased levels of intracellular cAMP. To investigate this, the effect of db-cAMP on receptor-dependent and -independent functions was examined in VSMC from SHR. For the dependent functions of G i , the effect of 0.5 mM of db-cAMP on the hormonal inhibitions of adenylyl cyclase activity was examined in VSMC from SHR and WKY rats. Results shown in Fig. 2A indicate that ANG II-, C-ANP 4 -23 -, and oxotremorine-mediated enhanced inhibition (35% for ANG II and 45% for C-ANP 4 -23 and oxotremorine) of adenylyl cyclase activity in VSMC from SHR compared with WKY rats was reversed toward WKY levels by db-cAMP. Receptor-independent functions. For receptor-independent functions, the effects of db-cAMP were investigated on the inhibitory effects of GTP␥S (10 Ϫ12 to 10 Ϫ7 M) on forskolinstimulated adenylyl cyclase activity in VSMC from SHR and WKY rats. The results shown in Fig. 2B indicate that the forskolin-stimulated adenylyl cyclase activity was inhibited by GTP␥S in a concentration-dependent manner in VSMC from SHR and WKY; however, the inhibition was significantly enhanced (28%) in VSMC from SHR compared with VSMC from WKY and was reversed to control levels by db-cAMP.
Implication (32, 63) , it was of interest to investigate the relative contribution of PKA and Epac in db-cAMP-induced effects on G i protein expression. To test this, we examined the effects of the Epac-selective cAMP analog CPT on the enhanced expression of G i proteins in VSMC from SHR and WKY rats and the PKA inhibitor KT on the db-cAMP induced attenuation of the enhanced expression of G i proteins in VSMC from SHR and WKY rats. As shown in Fig. 3 , KT reversed db-cAMP-induced attenuation of enhanced expression of G i ␣-2 (Fig. 3A) and Gi␣-3 (Fig. 3B) proteins in VSMC from SHR, whereas CPT did not significantly affect the levels of G i ␣ proteins in VSMC from both WKY and SHR. Furthermore, KT did not have any effect on the levels of G i ␣ proteins in VSMC from WKY.
db-cAMP attenuates the enhanced proliferation of VSMC from SHR. VSMC from SHR have been shown to exhibit enhanced proliferation compared with WKY rats (40) . Since cAMP regulates the cell growth, it was of interest to investigate if the decreased levels of intracellular cAMP reported in VSMC from SHR (2, 53) contribute to the enhanced prolifer- ation of VSMC of SHR. To test this, we examined the effect of db-cAMP on cell proliferation of VSMC from SHR and WKY rats, and the results are shown in Fig. 4 . As reported previously, VSMC from SHR exhibited enhanced proliferation (ϳ350%) compared with WKY as determined by [ 3 H]thymidine incorporation (Fig. 4A) , which was significantly attenuated by ϳ100% by db-cAMP. On the other hand, db-cAMP did not have any effect on the proliferation of VSMC from WKY. In addition, forskolin, an direct activator of adenylyl cyclase enzyme, also attenuated the enhanced proliferation of VSMC from SHR by 100%, whereas these antagonists did not reduce the proliferation of VSMC from WKY rats. Furthermore, the cell number as determined by Trypan blue dye exclusion assay was also increased by ϳ400% in VSMC from SHR, which was attenuated to control WKY levels by db-cAMP and forskolin (Fig. 4B) .
To further investigate if db-cAMP-induced antiprolifearative effect is mediated through the activation of PKA or Epac pathway, we examined the effect of KT and CPT on proliferation of VSMC in the presence or absence of db-cAMP, respectively, and the results are shown in Fig. 4C . KT reversed the antiproliferative effect of db-cAMP in VSMC from SHR, whereas CPT was without effect on the enhanced proliferation of VSMC from SHR. On the other hand, KT or CPT did not have any effect on the proliferation in VSMC from WKY rats.
Effect of db-cAMP on the enhanced production of superoxide anion and NAD(P)H oxidase activity in VSMC from SHR.
We showed earlier the role of oxidative stress in enhanced expression of G i ␣ proteins in VSMC from SHR (54) . In addition, a role of cAMP in attenuating oxidative stress induced by different interventions has been reported (57, 58, 60 -62) . It was of interest to examine if the enhanced oxidative stress exhibited by VSMC from SHR was also attributed to the decreased levels of intracellular cAMP. To examine this, the effect of db-cAMP on O 2 Ϫ production and NAD(P)H oxidase activity was investigated in VSMC from SHR. Results shown in Fig. 5 , indicate that the enhanced production of O 2 Ϫ (Fig. 5A ) and NAD(P)H oxidase activity (Fig. 5B) in VSMC from SHR compared with WKY rats were restored to control WKY levels by db-cAMP. On the other hand, db-cAMP did not have any effect on O 2 Ϫ production and NAD(P)H oxidase activity in VSMC from WKY rats.
db-cAMP attenuates the enhanced expression of NAD(P)H oxidase subunits in VSMC from SHR. The levels of different subunits of NAD(P)H oxidase, such as Nox1, Nox2, Nox4, p47 phox , and p22 phox have been reported to be upregulated in several tissues from SHR including VSMC (19, 20, 43, 64) . Since db-cAMP decreased the enhanced production of O 2 Ϫ and NAD(P)H oxidase activity in VSMC from SHR, it may be possible that the db-cAMP-evoked decrease in O 2 Ϫ production and NAD(P)H oxidase activity is associated with decreased expression of different subunits of NAD(P)H oxidase. To investigate this, the effect of db-cAMP on the expression of, Nox1, Nox2, Nox4, p47 phox , and p22 phox proteins was examined in VSMC from SHR and WKY rats. As shown in Fig. 6 , the expression of Nox4 (Fig. 6A ) and p47 phox (Fig. 6B) , which was significantly enhanced by ϳ50 and 45%, respectively, in VSMC from SHR compared with WKY rats, was attenuated in a concentration-dependent manner by db-cAMP, and at 0.5 mM, it was attenuated by 80 and 75%, respectively. In addition, the expression of Nox1 (Fig. 6C) and Nox2 (Fig. 6D) was also increased by ϳ50 and 25%, respectively, in VSMC from SHR compared with WKY rats and db-cAMP (0.5 mM) attenuated this increase by ϳ90%. However, db-cAMP did not have any effect on the expression of Nox1, Nox2, Nox4, and p47 phox proteins from WKY rats. On the other hand, the levels of p22 phox were not different in the two groups of rats (data not shown).
Implication of PKA and Epac in db-cAMP-induced attenuation of enhanced expression of NAD(P)H oxidase subunits in VSMC from SHR.
Since the effect of db-cAMP on G i proteins expression in VSMC from SHR is mediated by PKA, it was of interest to examine if db-cAMP-induced attenuation of enhanced expression of NAD(P)H oxidase subunits is also mediated by PKA or Epac pathway. To test this, we examined the effect of KT and CPT on the enhanced expression of Nox4 and p47 phox in VSMC from SHR in the presence or absence of db-cAMP, respectively. As shown in Fig. 7 , KT reversed the inhibitory effect of db-cAMP on the enhanced expression of Nox4 proteins in VSMC from SHR. On the other hand, CPT did not have any effect on the enhanced expression of Nox4 proteins in VSMC from SHR. In addition, KT and CPT did not have any significant effect on the expression of Nox4 proteins in VSMC from WKY rats. Similar results of KT and CPT were observed on the expression of p47 phox proteins (data not shown).
Effect of db-cAMP on the enhanced phosphorylation of EGF-R and PDGF-R in VSMC from SHR.
Since EGF-R and PDGF-R transactivation by enhanced levels of vasoactive peptides in VSMC from SHR has been shown to contribute to the enhanced expression of G i ␣ proteins (27, 55) , it was of interest to examine if the decreased levels of intracellular cAMP increase the expression of G i ␣ proteins through the transactivation of EGF-R and PDGF-R. To test this, the effects of db-cAMP on the phosphorylation of EGF-R and PDGF-R were examined in VSMC from SHR and WKY rats using specific phosphotyrosine antibodies. As shown in Fig. 8 , phospho-specificTyr 1173 -EGF-R (Fig. 8A) , and phospho-specific-Tyr 857 -PDGF-R (Fig. 8B ) detected a single band at 170 and 190 kDa corresponding to EGF-R and PDGF-R, respectively, in VSMC from both SHR and WKY rats. However, the extent of EGF-R and PDGF-R phosphorylation was greater by ϳ45 and 50%, respectively, in VSMC from SHR compared with VSMC from WKY rats, whereas the expression of total EGF-R and PDGF-R was not altered in VSMC from SHR compared with WKY. db-cAMP attenuated the increased phosphorylation of EGF-R and PDGF-R in a concentration-dependent manner, and at 1 mM, the enhanced phosphorylation of EGF-R and PDGF-R was inhibited to WKY control levels. However, this treatment did not have any significant effect on the phosphorylation of EGF-R and PDGF-R in VSMC from WKY rats.
db-cAMP attenuates the enhanced phosphorylation of c-Src in VSMC from SHR. Since c-Src is the upstream signaling molecule and contributes to the activation of EGF-R (27), it was desirable to examine if the enhanced activation of c-Src in VSMC from SHR is attributed to the decreased levels of intracellular cAMP. To test this, the effect of db-cAMP on the phosphorylation of c-Src was assessed in VSMC from SHR and WKY rats. Results shown in Fig. 9 indicate that the phosphorylation of Tyr 418 on c-Src was significantly augmented by ϳ75% in VSMC from SHR compared with WKY rats. db-cAMP attenuated the enhanced phosphorylation of c-Src in a concentration-dependent manner, and at 1 mM, it was completely restored to WKY levels.
Effect of db-cAMP on the enhanced phosphorylation of ERK1/2 in VSMC from SHR. Since the phosphorylation of ERK1/2 has been reported to be increased in VSMC from SHR (36) , it was of interest to examine the contribution of decreased levels of intracellular cAMP in the augmented phosphorylation of ERK1/2 in VSMC from SHR. To test this, the effect of db-cAMP was examined on ERK1/2 phosphorylation in VSMC from SHR and the results are shown in Fig. 10 . As reported earlier (36) , the phosphorylation of ERK1/2 was significantly augmented by ϳ40% in VSMC from SHR compared with WKY. db-cAMP treatment attenuated the enhanced phosphorylation of ERK1/2 in a concentration-dependent manner, and at 0.5 mM, it was completely attenuated to control levels. However, this treatment did not have any significant effect on ERK1/2 phosphorylation in VSMC from WKY rats.
DISCUSSION
We showed earlier that VSMC from SHR exhibit enhanced levels of G i ␣ proteins (4) and exaggerated cell growth (40) compared with VSMC from WKY rats. The implication of enhanced levels of endogenous ANG II and ET-1 and oxidative stress in enhanced expression of G i ␣ proteins and hyperproliferation has also been reported (27, 46, 55) . However, in the present study, we report for the first time that the augmentation of intracellular levels of cAMP by db-cAMP in VSMC of SHR attenuates the enhanced expression of G i ␣ proteins and hyperproliferation through the inhibition of ROS and ROS-mediated c-Src signaling pathways and suggest the contribution of decreased levels of intracellular cAMP in enhanced expression of G i ␣ proteins and hyperproliferation of VSMC from SHR.
We report that db-cAMP, a cell-permeable cAMP analog, attenuated the enhanced expression of G i ␣ proteins in VSMC from SHR to control levels, which was also reflected in the inhibition of the enhanced functions of G i ␣ as demonstrated by the attenuation of the enhanced inhibition of adenylyl cyclase by inhibitory hormones and forskolin-stimulated adenylyl cyclase activity by GTP␥S in VSMC from SHR. These results suggest that the decreased levels of intracellular cAMP may be responsible for the enhanced expression and functions of G i ␣-2 and G i ␣-3 proteins in VSMC from SHR. In this regard, db-cAMP was also shown to attenuate ANG II-induced enhanced expression of G i ␣ proteins in VSMC (37) . The role of decreased levels of cAMP in the enhanced expression of G i ␣ is further supported by our studies showing that the enhanced expression of G i ␣ in VSMC from L-NAME hypertensive rats was also attenuated by db-cAMP.
A role of cAMP in the regulation of proliferation of various cell types has been well documented (22, 25, 51) . cAMP was shown to stimulate the cell proliferation of epithelial cells, thyrocytes, hepatocytes, Swiss 3T3 cells, and keratinocytes, whereas it inhibits the proliferation of several cells including fibroblasts and smooth muscle cells (22, 25, 51) . In the present study, we report that the enhanced proliferation exhibited by VSMC from SHR may also be attributed to the decreased levels of intracellular cAMP, because augmenting the intracellular levels of cAMP by db-cAMP or forskolin, a cAMP- elevating agent, attenuated the enhanced proliferation of VSMC of SHR as determined by thymidine incorporation as well as by counting the cell number. In addition, the studies showing that ANG II-stimulated protein synthesis in rat aortic SMC was attenuated by the elevation of intracellular cAMP levels (26) further support the implication of reduced levels of intracellular cAMP in enhanced protein synthesis. The underlying mechanism by which db-cAMP attenuates the enhanced expression of G i ␣ proteins and hyperproliferation of VSMC from SHR appears to involve PKA and not Epac pathway, because the PKA inhibitor KT reversed the attenuating effect of db-cAMP on G i protein expression and proliferation, whereas the Epac-selective cAMP analog CPT was ineffective in altering these parameters in VSMC from SHR. Our results are in accordance with the studies of Goncharova et al. (29) , who have shown that the ␤-agonists and PGE 2 that increase the intracellular levels of cAMP inhibit PDGF-induced human airway smooth muscle cell migration via PKA activation. We previously showed the implication of ERK1/2 in ANG II-induced enhanced expression of G i ␣-2 and G i ␣-3 protein and cell proliferation in A10 VSMC as well as in VSMC from SHR (27, 28, 39, 40, 55) . In the present study, we show that the signaling mechanism by which decreased levels of intracellular cAMP increase the expression of G i proteins and cell proliferation of VSMC from SHR may involve the MAPK pathway because db-cAMP, which inhibited enhanced expression of G i proteins and enhanced proliferation, also attenuated the enhanced phosphorylation of ERK1/2. In this regard, cAMPelevating agents including isoproterenol, glucagon, and forskolin have been reported to inhibit MAPK activity in adipocytes (56) . In addition, PKA, the primary effector of cAMP signaling, was also shown to inhibit the MAPK/ERK cascade in many cell types including human arterial SMC (30, 60) .
The implication of growth factor receptor activation in enhanced expression of G i ␣ proteins and enhanced proliferation of VSMC from SHR has recently been shown (27, 40, 55) . In this study, we report the enhanced activation of EGF-R and PDGF-R in VSMC from SHR may also be attributed to the decreased levels of intracellular cAMP because db-cAMP that increases the intracellular levels of cAMP attenuated the enhanced phosphorylation of EGF-R and PDGF-R. These results suggest that growth factors receptor activation may be the underlying mechanism through which decreased levels of intracellular cAMP enhanced the expression of G i proteins and proliferation of VSMC in SHR. In this regard, the attenuation of PDGF-R activation by cAMP elevating agents has been shown by several investigators (30, 42) .
We also examined the upstream signaling mechanism activated by decreased levels of intracellular cAMP that lead to the transactivation of EGF-R and PDGF-R in VSMC from SHR. VSMC from SHR have been shown to exhibit enhanced levels of O 2 Ϫ (36) and enhanced expression of different subunits of NAD(P)H oxidase such as Nox1, Nox2, Nox4, and p47 phox (19, 54) . A role of reactive oxygen species (ROS) causing oxidative stress in growth factor receptor transactivation has been well established (9, 46, 58) . We reported earlier the implication of increased oxidative stress in the activation of MAPKs (36) and in the transactivation of growth factors receptors in VSMC from SHR (27, 40, 55) . In the present study, we demonstrate that the enhanced oxidative stress in VSMC from SHR that activate growth factor receptors is attributed to the decreased level of intracellular cAMP because increasing the intracellular levels of cAMP by db-cAMP attenuated the enhanced levels of O 2 Ϫ , enhanced activity of NAD(P)H oxidase, and enhanced expression of Nox1, Nox2, Nox4, and p47 phox protein in VSMC from SHR towards control WKY levels. In this regard, the role of cAMP in attenuating oxidative stress induced by different interventions has been reported. Cholera toxin that increases intracellular cAMP levels as well as dibutyryl cAMP has been shown to decrease the production of O 2 Ϫ stimulated by parathyroid hormone in bone resorbing osteoclasts (13) . Similarly, the cAMP elevating agents such as forskolin, IBMX, and db-cAMP were shown to decrease 2-deoxy-D-ribose-induced oxidative damage in pancreatic ␤-cells (35), whereas db-cAMP was shown to attenuate the production of ROS in granulocytes from normal healthy subjects (49) . In addition, theophylline, an inhibitor of cAMP phosphodiesterase, was shown to inhibit cadmiuminduced lipid peroxidation and oxidative stress in rat submandibular saliva (1) as well as diabetes-induced oxidative stress in rats (47) .
Our results showing that inhibition of PKA by KT reversed the attenuating effect of db-cAMP on the expression of Nox4 and p47 phox proteins and activation of Epac by CPT was without effect on the enhanced expression of these proteins in VSMC from SHR suggest the implication of the cAMP-PKA and not the cAMP-Epac pathway in db-cAMP-induced decreased expression of Nox4 and p47 phox proteins. In this regard, a role of the cAMP-PKA pathway in the attenuation of oxidative stress and Nox2 expression in response to klotho gene in rat VSMC has also been reported (59) .
The intervening molecule between oxidative stress and growth factor receptor transactivation was shown to be c-Src because the enhanced phosphorylation of c-Src exhibited by VSMC from SHR was inhibited by N-acetylcysteine, a scavenger of O 2 Ϫ (27, 40) , and the enhanced phosphorylation of PDGF-R and IGF-R was inhibited by c-Src inhibitor PP 2 in VSMC from SHR (27) . We now report that the decreased levels of intracellular cAMP may also be responsible for the enhanced phosphorylation of c-Src in VSMC from SHR because elevating the levels of intracellular cAMP by db-cAMP attenuated the enhanced phosphorylation of c-Src to control levels.
In conclusion, we have shown that cAMP attenuates the enhanced expression of G i ␣ proteins, hyperproliferation, oxidative stress, c-Src activation, activation of growth factor receptors such as EGF-R and PDGF-R, and MAPK signaling (Fig. 11) , all the signaling pathways that were shown to be implicated in the enhanced expression of G i ␣ proteins in VSMC from SHR. Thus it may be suggested that db-cAMP-induced attenuation of the increased expression of G i ␣ proteins and proliferation of VSMC from SHR may be attributed to its ability to inhibit the enhanced oxidative stress and downstream signaling pathways and that elevating the levels of cAMP in SHR may have protective effect against oxidative stress-induced vascular complications in hypertension.
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